

COX-2 Inhibitors and Cardiovascular Risk: Deciphering the Mystery

By Mimi Lo, Pharm.D.

References

1. Topol, EJ. Failing the public health – rofecoxib, Merck, and the FDA. *NEJM* 2004 (Oct 21); 351(17): 1707-1709.
2. FDA alert for practitioners: Celebrex (celecoxib) [webpage]. Dec 17, 2004 www.fda.gov/cder/drug/infopage/celebrex/celebrex-hcp.pdf. Last accessed 2/8/05.
3. Bextra^R valdecoxib tablets [package insert]. G.D. Serale LLC; New York. Revised 11/2004 www.fda.gov/cder/foi/label/2004/213411bl.pdf. Last accessed 2/8/05.
4. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. *NEJM* 2000 (Nov 23); 343(21): 1520-1528.
5. Simmons DL, Botting RM, HLA T. Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. *Pharmacol Rev* 2004; 56(3): 387-437.
6. Clark DW, Layton D, Shakir SA. Do some inhibitors of COX-2 increase the risk of thromboembolic events? Linking pharmacology with pharmacoepidemiology. *Drug Safety* 2004; 27(7): 427-456.
7. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. *FASEB J* 2004; 18 (May): 790-804.
8. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. *Proc Natl Acad Sci, USA* 1999; 96 (June): 7563-7568.
9. Van Hecken A, Schwartz JI, Depré M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. *J Clin Pharmacol* 2000; 40: 1109-1120.
10. Justice E, Carruthers DM. Cardiovascular risk and COX-2 inhibition in rheumatological practice. *J Human Hypertention* 2004 (Sept 23); 1-5.
11. FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. *Nat Rev Drug Discov* 2003 (Nov); 2(1): 879-890.
12. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. *Lancet* 1998; 351 (June 13): 1755-1762.
13. Cheng HF, Harris RC. Cyclooxygenases, the kidney, and hypertension. *Hypertension* 2004 (March); 43(3): 525-30.
14. Harris RC. Cyclooxygenase-2 inhibition and renal physiology. *Am J Cardiol* 2002 (Mar 21); 89(6A): 10D-17D.
15. Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal

(Continued on page 2)

A University of Washington Drug Information Center publication
Distributed monthly by authority of the Pharmacy and Therapeutics Committee
Editor: Nelda A. Murri, Pharm.D. (206) 598-6612 – Asst. Editor: Elizabeth Rudy, D.V.M., R.Ph.
Department of Pharmacy Services / School of Pharmacy

Copyright © 2005 by the University of Washington
Also published on the World Wide Web at <http://uw.prnrx.org/therapyTopics.asp>
No material may be reproduced in whole or in part without written permission from the editor.

References
(continued)

- event trial (TARGET), cardiovascular outcomes: randomised controlled trial. *Lancet* 2004; 364 (August 21): 675-684.
16. Keane WF. Merck announces voluntary worldwide withdrawal of Vioxx [Dear Healthcare Professional Letter]. September 30, 2004. www.vioxx.com/vioxx/documents/english/hcp_notification_physicians.pdf. Last accessed 2/8/05.
 17. Reicin AS, Shapiro D, Sperling RS, et al. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). *Am J Cardiol* 2002; 89 (Jan 15): 204-209.
 18. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled clinical trials of rofecoxib. *Circulation* 2001; 104 (Nov 6): 2280-2288.
 19. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. *J Thor Card Surg* 2003 (June); 125(6): 1481-1492.
 20. Furberg CD, Psaty BM, FitzGerald GA. Parecoxib, valdecoxib, and cardiovascular risk [editorial]. *Circulation* 2005 (Jan 25); 111(3): 249.
 21. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. *JAMA* 2000 (Sept 13); 284(10): 1247-1255.
 22. White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. *Am J Cardiol* 2002; 89 (Feb 15): 425-430.
 23. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. *Circulation* 2004; 109 (May 4): 2068-2073.
 24. Pfizer statement on new information regarding cardiovascular safety of Celebrex [Investor News Release]. Pfizer; New York. December 17, 2004. www.pfizer.com/are/investors_releases/2004pr/mn_2004_1217.cfm. Last accessed 2/8/05.
 25. Sowers JR, White WB, Pitt B, et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. *Arch Intern Med* 2005 (Jan 24); 165 (2): 161-168.
 26. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), reduction in ulcer complications: randomised controlled trial. *Lancet* 2004; 364 (August 21): 665-674.
 27. Chan FK, Graham DY. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications—review and recommendations based on risk assessment. *Aliment Pharmacol Ther* 2004; 19: 1051-1061.
 28. Schnitzer TJ. Update of ACR guidelines for osteoarthritis: role of the coxibs. *J Pain Symptom Manage* 2002 (April); 23 (4S): S24-S30.